Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

@article{Wardley2005ZoledronicAS,
  title={Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration},
  author={Andrew M Wardley and Neville G Davidson and Peter J. Barrett-Lee and Angela Hong and Janine L. Mansi and David J. Dodwell and Rachel Murphy and Teresa Mason and David A. Cameron},
  journal={British Journal of Cancer},
  year={2005},
  volume={92},
  pages={1869 - 1876}
}
Patients with bone metastases from breast cancer often experience substantial skeletal complications – including debilitating bone pain – which negatively affect quality of life. Zoledronic acid (4 mg) has been demonstrated to reduce significantly the risk of skeletal complications in these patients and is administered via a short, 15-min infusion every 3 weeks, allowing the possibility for home administration. This study compared the efficacy and safety of zoledronic acid administered in the… CONTINUE READING